Advertisement

Pharmacy World & Science

, Volume 30, Issue 1, pp 44–50 | Cite as

Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting

  • Marianna AlacquaEmail author
  • Gianluca Trifirò
  • Vincenzo Arcoraci
  • Eva Germanò
  • Angela Magazù
  • Tiziana Calarese
  • Giuseppa Di Vita
  • Catalda Gagliano
  • Edoardo Spina
Research Article

Abstract

Objective To analyse the prescribing pattern and the safety profile of different atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs) during the years 2002–2003 in paediatric setting. Setting Two Child Neurology and Psychiatry Divisions of Southern Italy (University of Messina and “Oasi Institute for Research on Mental Retardation and Brain Aging” of Troina). Methods A retrospective chart review of all children and adolescents starting an incident treatment with atypical antipsychotics or SSRIs was performed. Within the first 3 months of therapy, any potential adverse drug reaction (ADR) was identified and the clinical outcome of psychotropic drug treatment was assessed. Main Outcome Measure Rate of ADR in the first 3 months of therapy with atypical antipsychotics and SSRIs in children and adolescents. Results On a total of 97 patients’ charts being reviewed, 73 (75%) concerned atypical antipsychotics and 24 (25%) SSRIs. Risperidone (N = 45, 62%) was the most frequently prescribed antipsychotic drug, followed by olanzapine (24, 32%). Overall, 50 (68%) antipsychotic users reported a total of 108 ADRs during the first 3 months of therapy, leading to drug discontinuation in 23 patients (31%). Among 24 users of SSRI, 12 (50%) received paroxetine, 6 (25%) sertraline, 5 (21%) citalopram and 1 (4%) fluoxetine. Only paroxetine users (21%) reported at least one ADR, however, none of SSRI users withdrew drug treatment within first 3 months. Conclusions ADRs occurred frequently during first 3 months of treatment with atypical antipsychotics and, to a lesser extent, with SSRIs in children and adolescents. Further investigations are urgently needed to better define the benefit/risk ratio of psychotropic medications in paediatric setting.

Keywords

Adolescents Adverse drug reactions Atypical antipsychotics Children Italy Selective serotonin reuptake inhibitors 

Notes

Acknowledgments

The authors thank child and adolescent psychiatrists working at University of Messina and “Oasi Institute for Research on Mental Retardation and Brain Aging” of Troina for their active cooperation.

References

  1. 1.
    Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT. Psychotropic medication in children: a study from the Netherlands. Pediatrics 2001;108:E25.PubMedCrossRefGoogle Scholar
  2. 2.
    Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283:1059–60.CrossRefGoogle Scholar
  3. 3.
    ‘T Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Stricker BH. Unlicensed and off label prescription of drugs to children: population based cohort study. BMJ 2002;324:1313–4.CrossRefGoogle Scholar
  4. 4.
    Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999;88:965–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004;65:30–44.PubMedGoogle Scholar
  6. 6.
    Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:372–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Henry CA, Steingard R, Venter J, Guptill J, Halpern EF, Bauman M. Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review. J Child Adolesc Psychopharmacol 2006;16:187–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Wilens TE, Biederman J, Kwon A, et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003;13:143–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Hazell P, O’Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002;CD002317.Google Scholar
  10. 10.
    Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine Pediatric OCD Study Team. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001;40:773–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Masi G, Toni C, Mucci M, Millepiedi S, Mata B, Perugi G. Paroxetine in child and adolescent outpatients with panic disorder. J Child Adolesc Psychopharmacol 2001;11:151–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Walkup J, Labellarte M, Riddle MA, et al. Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. J Child Adolesc Psychopharmacol 2002;12:175–88.PubMedCrossRefGoogle Scholar
  14. 14.
    Committee on Safety of Medicines. Selective serotonin reuptake inhibitors: overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. Available from: http://www.medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/ssrioverview_101203.htm (accessed 19 April 2006).
  15. 15.
    Ma J, Lee KV, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 2005;37:434–42.PubMedCrossRefGoogle Scholar
  16. 16.
    US Food and Drug Administration, Suicidality in Children and Adolescents Being Treated With Antidepressant Medications (2004) October 15. Available from: http://www.fda.gov/cder/drug/antide pressants/ssripha200410.htm (accessed 19 April 2006).
  17. 17.
    Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviours. JAMA 2004;292:338–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.PubMedCrossRefGoogle Scholar
  19. 19.
    Arango C, Parellada M, Moreno DM. Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 2004;14:471–9.CrossRefGoogle Scholar
  20. 20.
    Gagliano A, Germano E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 2004;14:39–47.PubMedCrossRefGoogle Scholar
  21. 21.
    Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:634–41.CrossRefGoogle Scholar
  22. 22.
    McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004;65:20–9.PubMedGoogle Scholar
  23. 23.
    Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000;57:238–55.PubMedGoogle Scholar
  24. 24.
    Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15:885–92.PubMedCrossRefGoogle Scholar
  25. 25.
    Masi G, Cosenza A, Mucci M. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 2001;11:389–94.PubMedCrossRefGoogle Scholar
  26. 26.
    Toren P, Ratner S, Laor N, Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 2004;27:1135–56.PubMedCrossRefGoogle Scholar
  27. 27.
    Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric out patients. Br J Clin Pharmacol 2002;54:665–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 2001;3:927–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Diler RS, Avci A. Selective serotonin reuptake inhibitors in children and adolescents. Swiss Med Wkly 2002;132:470–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Marianna Alacqua
    • 1
    Email author
  • Gianluca Trifirò
    • 1
    • 4
  • Vincenzo Arcoraci
    • 1
  • Eva Germanò
    • 2
  • Angela Magazù
    • 2
  • Tiziana Calarese
    • 2
  • Giuseppa Di Vita
    • 3
  • Catalda Gagliano
    • 3
  • Edoardo Spina
    • 1
    • 4
  1. 1.Department of Clinical and Experimental Medicine and Pharmacology, Pharmacology UnitUniversity of MessinaMessinaItaly
  2. 2.Division of Child Neurology and PsychiatryUniversity of MessinaMessinaItaly
  3. 3.Oasi Institute for Research on Mental Retardation and Brain Aging (IRCCS)TroinaItaly
  4. 4.IRCCS Centro Neurolesi “Bonino-Pulejo”MessinaItaly

Personalised recommendations